Clinical trial
A Study Multicenter Randomized to Assess the Efficacy and Toxicity of Adding Metronomic Therapy to the Standard Treatment of Patients With High Grade Malignant Osteosarcoma With Metastatic Lung Disease at Diagnosis and Primary Resectable Tumor: A Study by the Latin American Group for Treatment of Osteosarcoma
NCT03063983 is registered in ClinicalTrials.gov with Grupo de Apoio ao Adolescente e a Crianca com Cancer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study Multicenter Randomized to Assess the Efficacy and Toxicity of Adding Metronomic Therapy to the Standard Treatment of Patients With High Grade Malignant Osteosarcoma With Metastatic Lung Disease at Diagnosis and Primary Resectable Tumor: A Study by the Latin American Group for Treatment of Osteosarcoma
- Lead sponsor
- Grupo de Apoio ao Adolescente e a Crianca com Cancer
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 2, 2017
- Completion date
- January 31, 2022
- Enrollment
- 158 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.